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Abstract During the last two decades, new insights into
proteasome function and its role in several human diseases
made it a potential therapeutic target. In this context,
Amblyomin-X is a Kunitz-type FXa inhibitor similar to
endogenous tissue factor pathway inhibitor (TFPI) and is a
novel proteasome inhibitor. Herein, we have demonstrated
Amblyomin-X cytotoxicity to different tumor cells lines
such as pancreatic (Panc1, AsPC1BxPC3) and melanoma
(SK-MEL-5 and SK-MEL-28). Of note, Amblyomin-X was
not cytotoxic to normal human fibroblast cells. In addition,
Amblyomin-X promoted accumulation of ER stress
markers (GRP78 and GADD153) in sensitive (SK-MEL-
28) and bortezomib-resistant (Mia-PaCa-2) tumor cells.
The intracellular calcium concentration [Ca2?]i was
slightly modulated in human tumor cells (SK-MEL-28 and
Mia-PaCa-2) after 24 h of Amblyomin-X treatment. Fur-
thermore, Amblyomin-X induced mitochondrial dysfunc-
tion, cytochrome-c release, PARP cleavage, and activation
of caspase cascade in both human tumor (SK-MEL-28 and
Mia-PaCa-2) cells. These investigations might help in
further understanding of the antitumor properties of
Amblyomin-X.
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ER Endoplasmic reticulum
[Ca2?]i Intracellular calcium concentration
ERAD ER-associated degradation
UPR Unfolded protein response
GRP78 78 kDa glucose-regulated protein; kinase-
like ER kinase (PERK), the inositol requiring
kinase 1 alpha (IRE1a), and the transcription
factor-activating transcription factor 6
(ATF6)
eIF2a Alpha subunit of translation initiation factor
GADD153 Nuclear transcription factors of growth arrest
and DNA damage
TRAF2 Tumor necrosis factor TNF receptor-
associated factor (TRAF) 2
JNK c-Jun-N-terminal kinase
123Rh Rhodamine 123
TAPS Thapsigargin
PARP A 116 kDa nuclear poly (ADP-ribose)
polymerase
TFPI Tissue factor pathway inhibitor
TF Tissue factor
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
PERK Protein kinase-like ER kinase
IRE1a Inositol requiring kinase 1 alpha
ATF6 Transcription factor-activating transcription
factor 6
ATF4 Actor-activating transcription factor 4
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Introduction
The proteasome is a large protein complex responsible
for regulation of intracellular proteolysis in all eukaryotic
cells. Thereby, it plays an essential role in the regulation
of the cellular processes, including protein quality control,
cell cycle progression, differentiation, signal transduction,
apoptosis, gene expression, and antigen processing [1–3].
Thus, a dysfunction of proteasome activity has detri-
mental effect on cell homeostasis. In humans, proteasome
deregulation has numerous implications in pathologies
such as cancer, autoimmune diseases, neurodegenerative
diseases, and viral infections [1–3], rendering it as a
potential therapeutic target [2]. A proteasome inhibitor
bortezomib is approved by FDA for the treatment of
multiple myeloma, and several others are in clinical trials
[3].
Cell death induced by proteasome inhibitors could
involve endoplasmic reticulum (ER) stress [4–7]. Impor-
tant steps in the synthesis of the proteins directed to the
secretory pathway or to plasma membrane are processed in
the ER-lumen, such as folding and post-translational
modifications [8, 9]. However, if correct folding is not
reached, the first quality control system (calnexin/calreti-
culin) works to bring proteins in the correct folding [8].
Many misfolded proteins undergo this quality control
system and can be eliminated via the proteasome, by a
mechanism known as endoplasmic reticulum-associated
protein degradation (ERAD) [10, 11]. The inhibition of this
process ultimately leads to the accumulation and aggre-
gation of proteins in the ER and the induction of ER stress
[8, 11]. Thus, ERAD fine-tuning is essential for pro-
teostasis [10]. Despite no direct association, ERAD could
share common pathways with unfolded protein response
(UPR), for instance, IRE1-dependent transcription factor
XBP1 codes for several ERAD-related genes [10, 12].
Overall, those pathways underline key ubiquitin–protea-
some system functions related to un/misfolded protein
disposal and cell stress response.
During UPR activation, the chaperone 78 kDa glu-
cose-regulated protein (GRP78) is released from three
ER transmembrane proteins: protein kinase-like ER
kinase (PERK); the inositol requiring kinase 1 alpha
(IRE1a); and the transcription factor-activating tran-
scription factor 6 (ATF6) [13, 14]. The ER transmem-
brane proteins IRE1a and PERK undergo dimerization
and auto-phosphorylation and are consequently activated
that redirect alternative transcription of chaperones and
transcription factors, such GRP78 and factor-activating
transcription factor 4 (ATF4) [15]. PERK phosphorylates
the eukaryotic translation initiation factor (eIF)2a and
results in a global attenuation of protein translation.
These events help the cell to cope with accumulated
unfolded proteins and restore ER homeostasis. In paral-
lel, ATF6 is transported to the Golgi, where it is
sequentially cleaved by Golgi resident proteases, result-
ing in the release of cytosolic domain of ATF6, which
goes to the nucleus to activate the transcription of target
genes (GRP78, GADD153, calreticulin) [16]. However,
failure to relieve prolonged or severe ER stress, triggers
apoptosis [8].
If ER stress is persistent or severe and ER homeostasis
is not restored, UPR activates cell death pathways. One of
ER stress-induced cell death pathways is mediated by
IRE1 that can interact with the adaptor protein of TNF
receptor-associated factor 2 (TRAF2), leading to the
activation of apoptosis signal-regulating kinase 1 [17].
This might mediate apoptosis in response to ER stress by
activation of c-Jun-N-terminal kinase (JNK). The com-
plex IRE1a/TRAF2 also activates ER-resident caspase-4
[17]. Furthermore, ATF4 can lead to the upregulation of
nuclear transcription factors of growth arrest and DNA
damage (GADD153). This able cells to (i) transcription-
ally down-regulate the levels of Bcl-2 and upregulate
DR5; (ii) cause cell cycle arrest; (iii) sensitize the mito-
chondria to pro-apoptotic Bcl-2 family proteins; (iv) lead
to a depletion of the cellular glutathione levels and
increase levels of reactive oxygen species [18–20]. In
addition, calcium released from the ER is rapidly taken
up by the mitochondria, where it leads to collapse of inner
membrane potential, cytochrome-c release, caspase cas-
cade activation, and subsequent initiation of apoptosis
[21–23].
In this context, Amblyomin-X is a homolog of Kunitz-
type protein identified in the transcriptome of the salivary
glands from the adult Amblyomma cajennense tick [24, 25].
The recombinant protein form of Amblyomin-X has pre-
sented antitumor activity via induction of apoptosis and
inhibition of proteasome [26, 27]. The human melanoma
(SK-MEL-28) and human pancreas adenocarcinoma (Mia-
PaCa-2) tumor cells were a good choice to investigate the
mechanism of action of Amblyomin-X, because both of
them are sensitive to pro-apoptotic effects of Amblyomin-
X [24]. In addition, Mia-PaCa-2 cells are resistant to
bortezomib-induced apoptosis [28]. In this study, we
reported pro-apoptotic effect of Amblyomin-X in these
human tumor cells associated to inhibition of proteasome
function, ER stress (UPR markers upregulation), mobi-
lization of [Ca2?]i, mitochondrial dysfunction, PARP
cleavage, and caspase-3 activation. Interestingly, none of
these changes were observed in normal human fibroblast
cells.
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Results
Amblyomin-X induces cytotoxicity in human tumor
cells
The effect of Amblyomin-X (1 lM) on cell viability of
human melanoma (SK-MEL-28 and SK-MEL-5) and
pancreatic (Mia-PaCa-2, Panc1, AsPC1, and BxPC3) tumor
cells was investigated. After 48 h, cells treated with
Amblyomin-X decreased the viability considerably as
shown in Table 1. The amount of viable cells was different
for both tumors cells; for example,*67 % of Mia-PaCa-2
and*29 % of metastatic-derived AsPC1 were viable after
48 h of Amblyomin-X treatment (Table 1). However, no
changes in cell viability of human fibroblast were observed
after 48 h of Amblyomin-X treatment (Table 1).
Amblyomin-X triggers ER stress in tumor cells
It has been reported that Amblyomin-X inhibits protea-
some system [26, 27]. The inhibition of proteasome can
cause ER stress, thus, we decided to assess whether
Amblyomin-X could induce ER stress. A representative of
human melanoma and pancreatic tumor cells lines i.e.,
Mia-PaCa-2 and SK-MEL-28 were selected for this study,
since the effect of Amblyomin-X on the protein clearance
in those tumor cells has been investigated [29]. Human
fibroblast were used as non-tumor cell model.
The mRNA levels of the proteins related to the ER stress
were estimated using real-time PCR. When SK-MEL-28
cells are treated with 0.5 lM of Amblyomin-X, the mRNA
levels of IRE1a, ATF4, and GRP78 genes increased after
2 h and only GADD153 gene expression augmented in a
time-dependent manner but was significant only after 4 h
(Fig. 1a). The expression of the caspase-4 gene increased
after 24 h of treatment with Amblyomin-X. On the other
hand, the expression of the eIF2a gene did not increase in
the SK-MEL-28 cells treated with 0.5 lM Amblyomin-X
(Fig. 1a). In Mia-PaCa-2 cells treated with 0.5 lM of
Amblyomin, the expression of IRE1a and GADD153 genes
increased after 24 h (Fig. 1a). The GRP78, ATF4, eIF2a,
and caspase-4 genes showed no significant changes in
expression when compared to their corresponding controls.
Moreover, we verified the protein levels of GRP78 and
GADD153 in tumor cells after Amblyomin-X treatment.
The GRP78 protein levels increased in SK-MEL-28 after
4 h and in Mia-PaCa-2 after 24 h (Fig. 1b). The GADD153
protein levels increased after 24 h in both cells lines
(Fig. 1b). Human fibroblast cells showed some alterations
in IRE1a and eIF2a gene after 24 h of Amblyomin-X
treatment (Fig. 1b). In contrast, no alterations were found
in GRP78 and GADD153 protein levels in human fibrob-
last after Amblyomin-X treatment.
It is well established that ATF-6a and cargo proteins are
transported from the ER to the Golgi apparatus through the
ER-Golgi intermediate compartment (ERGIC) [30, 31] and
ERGIC-53 is a specific marker for ERGIC [31]. As shown
in Fig. 1c, anti-ATF-6a antibody stained cytoplasmic in
‘‘Ctrl’’ tumor cells. In contrast, ATF-6a moved toward and
reached the nucleus of tumor cells treated with Amblyomin-
X. Importantly, ATF6 staining overlapped with ERGIC-53,
and the images suggest close proximity to nucleus.
Amblyomin-X modulates mobilization of [Ca21]i
in tumor cells
We further investigated whether treatment with Ambly-
omin-X would cause the mobilization of [Ca2?]i in SK-
MEL-28 cells using microfluorimetry. We observed a
sustained but not a statistical increase in the [Ca2?]i, after
the application of 0.5 lM of Amblyomin-X (Fig. 2a, b). In
human fibroblast, no alterations were observed (Fig. 2a, b).
In the positive control cells treated with TAPS (1 lM) a
change in fluorescence signal was observed in both cell
types. In Ctrl, cells were treated with PBS which showed
no fluorescence alteration (Fig. 2a, b).
Table 1 Effect of Amblyomin-
X in cell viability of different
tumor cell lines
Tumor cell line Origin Viability
Mia-PaCa-2 Human pancreatic adenocarcinoma 67.02 ± 5.9***
Panc1 Human pancreatic epithelioid carcinoma 35.81 ± 1.2**
AsPC1 Human pancreatic adenocarcinoma 29.56 ± 1.03**
BxPC3 Human pancreatic adenocarcinoma 13.89 ± 0.50**
SK-MEL-28 Human melanoma 43.91 ± 10.5**
SK-MEL-5 Human melanoma 42.34 ± 13.75**
Human Fibroblast Non-tumor cell 106.76 ± 10.01
Tumor cells lines were incubated with 1 lM of Amblyomin-X for 48 h, and cell viability was assessed as
described in Materials and Methods. The data presented as the mean ± SD of three independent
experiments
**p B 0.005, ***p B 0.001 compared with the control group (corresponding untreated cells), as deter-
mined by one-way ANOVA
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Fig. 1 Amblyomin-X induces ER stress in tumor cells. a Cells were
treated with Amblyomin-X (0.5 lM) at the indicated times and levels
of gene expression of targets related to ER stress were evaluated by
real-time PCR. b After the indicated period of treatment, cells were
lysed with RIPA buffer and 30 lg of total protein was used for the
tests. Western blot analysis was performed by checking anti-GRP78,
anti-GADD153, and anti-GAPDH (endogenous controls). c Confocal
microscopy analysis of indirect immunofluorescence of ATF-6a and
ERGIC53. Cells treated with vehicle (PBS), or with 0.5 lM of
Amblyomin-X for 4 or 24 h, or with MG-132 (2.5 lM) and TAPS
(1 lM) for 24 h each. The final overlay image is a representative of
three independent experiments in which red fluorescence represents
ATF-6a, while green fluorescence represents ERGIC53, and yellow
corresponds to merging of both red and green. Values are
mean ± SD of three independent experiments. *p B 0.05;
**p B 0.01, and ***p B 0001. (Color figure online)
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Fig. 2 Amblyomin-X increases intracellular calcium levels in SK-
MEL-28 cells. a [Ca2?]i levels of unstimulated SK-MEL-28 and
human fibroblast cells were measured for 20 s, followed by addition
(marked by arrows) of Amblyomin-X (1 lM), TAPS (1 uM), or 50
uL of PBS 1X (Ctrl), and monitored for more than 100 s by
microfluorimetry. b Graphic representation of quantitative measure-
ments of fluorescence intensity (max–min) obtained from a. c Cells
were treated with Amblyomin-X, stained with calcium green-1, and
analyzed by flow cytometry. Representative histograms are expressed
in fluorescence intensity. d Bars graph and geometric mean
(fluorescence intensity) values ± SD obtained from C (three inde-
pendent experiments). e Cells were pre-incubated for 30 min with
BAPTA-AM (10 lM), followed by incubation with Amblyomin-X
(1 lM) for 48 h at 37 C
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Next, we assessed the mobilization of [Ca2?]i in SK-
MEL-28 and Mia-PaCa-2 cells at 4 and 24 h after treat-
ment of Amblyomin-X using fluorescence calcium Green-1
AM indicator in flow cytometry. The mobilization of
[Ca2?]i increased in both tumor cells after 24 h of
Amblyomin-X treatment compared to control (Fig. 2c, d).
The pre-treatment with BAPTA-AM protected the tumor
cells from Amblyomin-X cytotoxicity (Fig. 2e).
Amblyomin-X affect the mitochondria integrity
We investigated whether the Amblyomin-X causes mito-
chondrial dysfunction. In SK-MEL-28 and Mia-PaCa-2
cells treated with 0.5 lM of Amblyomin-X, the mito-
chondrial membrane changed slightly after 4 h. The
mitochondrial membrane potential changed significantly in
both cell lines after 24 h of its treatment with Amblyomin-
X, but was more pronounced in SK-MEL-28 (Fig. 3a, b).
Considering mitochondrial dysfunction induced by
Amblyomin-X could result in the release of pro-apoptotic
factors (such as cytochrome-c) into the cytoplasm, the
cytoplasmic levels of the cytochrome-c were determined
by Western blotting, which was increased after 48 h in the
cell lines treated with 0.5 lM of Amblyomin-X (Fig. 3c).
Caspase cascade activation in tumor cells
by Amblyomin-X
The release of cytochrome-c from mitochondria to cyto-
plasm causes the activation of caspase cascades via cas-
pase-3 leading to apoptosis [32]. Thus, we pre-incubated
tumor cells for 2 h with pan caspase inhibitor ZVAD-
FMK. Subsequently, Amblyomin-X was added to the
tumor cells and grown for further 48 h at 37 C as dis-
cussed in materials and methods. Tumor cells overcome
cytotoxicity of Amblyomin-X, bringing the viability to
*100 % in SK-MEL-28 and *92 % in Mia-PaCa-2 cells
(Fig. 4a). Likewise, when tumor cells were pre-incubated
with caspase-3 inhibitor DEVD-CHO, cell viability was
*86 % in SK-MEL-28 and *87 % in Mia-PaCa-2 cells.
When those tumor cells were not pre-treated with caspases
inhibitors, cell viability was *45 % in SK-MEL-28 and
*60 % in Mia-PaCa-2 cells treated with 0.5 lM Ambly-
omin-X (Fig. 4a).
We also quantified caspase 3/7 activity measuring the
fluorogenic response resulting from DEVD peptide cleav-
age. As shown in Fig. 4b, c, Amblyomin-X increased
caspase 3/7 activity compared to negative controls. MG-
132 and TAPS were used as positive control.
Next, we determined PARP cleavage using Anti-PARP
antibody as discussed in materials and methods. PARP is a
116-kDa nuclear (ADP-ribose) polymerase involved in
DNA repair predominantly in response to environmental
stress [33]. This protein could be cleaved by caspase-3 and
7 [34, 35] facilitating disassembling of the cellular com-
ponents and this serves as a marker for cells undergoing
apoptosis [33]. We evaluated PARP cleavage in tumor cells
treated with Amblyomin-X. A cleaved PARP band
observed in SK-MEL-28 cell after both 24 and 48 h of
Amblyomin-X treatment (Fig. 4d). In Mia-PaCa-2 cells, a
faint PARP cleavage band was observed after 24 h, which
becomes prominent after 48 h of Amblyomin-X treatment
(Fig. 4d). In human fibroblast, cleaved PARP band was not
detected (Fig. 4d).
Discussion
Recently, it has been demonstrated that Amblyomin-X
induces apoptosis in murine and human tumor cell lines
[26, 27]. Herein, we demonstrated unprecedented results of
Amblyomin-X cytotoxic effect on four tumor cells lines
(Panc1, BxPC3, AsPC1, and SK-MEL-5). The amount of
viable cells was different for both tumors cells treated with
Amblyomin-X, which could be associated to the features of
these cells. For example, Mia-PaCa-2 tumor cells derived
from the pancreas adenocarcinoma of a 65-year-old man do
not express measurable amounts of carcinoembryonic
antigen [36, 37]. On the other hand, AsPC1 cells obtained
from a 62-year-old woman produce abundant mucin as
well as carcinoembryonic antigen [36, 38]. Human pan-
creatic cells sensitive to Amblyomin-X (Table 1) have
mutation in the KRAS (v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog) and BxPC-3 is the wild-type exception
[36]. Amblyomin-X sensitive human melanoma cells have
mutant BRAF gene that increases kinase activity of BRAF,
leading to constitutive activation of the RAS-RAF-MEK-
ERK pathway and thus uncontrolled tumor proliferation
[39, 40]. Obviously, the features of cells tested generate
different levels of migration, invasion, tumorigenicity, and
chemosensitivity. Despite that, all cells lines were sensitive
to Amblyomin-X. SK-MEL-28 is sensitive to bortezomib
[41], but Mia-PaCa-2, Panc1, and AsPC1 are resistant to
this proteasome inhibitor [28]. In general, bortezomib-re-
sistant cells overexpressed the b5 subunit (a target of
bortezomib and have chymotrypsin-like activity) [42],
which has a mutation in the binding site for bortezomib
[42] or in downstream protein of the enzymatic complex
[43]. In fact, Amblyomin-X inhibits the trypsin-like
activity of the proteasome in tumor cells and indicates a
similar interaction with b2 subunit, which is under inves-
tigation. Thereby, proteasome inhibition and/or other but
yet unknown actions had made pancreatic cells sensitive to
Amblyomin-X. These findings together with previous
studies suggest that Amblyomin-X could function as a
broad-spectrum antitumor drug. Of note, no alterations in
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cell viability of human fibroblast were observed, suggest-
ing that Amblyomin-X is preferentially cytotoxic to tumor
cells.
Here, we selected SK-MEL-28 and Mia-PaCa-2 in this
study, since the role Amblyomin-X in protein clearance in
these tumor cells have already been demonstrated [26, 29].
Fig. 3 Mitochondrial dysfunction induced by Amblyomin-X in
tumor cells. a Histogram representing the mitochondrial membrane
potential. Cells were treated with Amblyomin-X (0.5 lM) for 4 h and
24 h. b Bars graph (fluorescence intensity) values ± SD obtained
from a (three independent experiments). c After the indicated periods
of treatments, cells were lysed. The cytoplasm and membrane were
separated and 30 lg of cytoplasmic protein fractions was separated on
SDS-PAGE. The Western blot of the samples was performed using
anti-cytochrome-c and anti-GAPDH (endogenous control)
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In fact, the data showed ER homeostasis disruption in
tumor cells, since expressions of some genes of UPR and
GRP78/GADD153 protein levels were elevated by
Amblyomin-X treatment, as well as ATF-6a transport. An
interesting point was the onset of ER stress responses (UPR
gene expression at 2 h and GRP78 proteins levels at 4 h) in
SK-MEL-28 cells prior to that induced via proteasome
inhibition by Amblyomin-X. Thus, we cannot rule out the
signaling independent proteasome inhibition. In fact, we
need more investigation regarding ERAD process in tumor
cells treated with Amblyomin-X. The changes in human
fibroblast cells after Amblyomin-X treatment were differ-
ent from those observed in tumor cells, i.e., the IRE1a and
eIF2a levels increased but there was no modulation in
GRP78/GADD153 levels.
In addition, perturbations of ER could compromise its
function because it is one of the major intracellular Ca2?
storages. We observed no increase in [Ca2?]i immediately
after Amblyomin-X application in SK-MEL-28 cells
(Fig. 2a, b), but not in human fibroblast cells. However, we
noticed that the increase in [Ca2?]i induced by Ambly-
omin-X was not transient, but proportional to the
Fig. 4 Caspase cascade activation after Amblyomin-X treatment in
tumor cells. a Cells were pre-incubated for 2 h with ZVAD-FMK
(50 lM) or DEVD-CHO (10 lM) followed by incubation with
Amblyomin-X (1 lM) for 48 h at 37 C. b Caspase activity was
measured using CellEventTM Caspase-3/7 Green Detection Reagent
(Molecular Probes), according to manufacturer’s instructions. Cells
treated with vehicle (PBS), or 0.5 lM of Amblyomin-X for 48 h, or
with MG-132 (2.5 lM) and TAPS (1 lM) for 24 h each. Then, cells
were stained with CellEventTM Caspase-3/7 Green Detection Reagent
and were analyzed by flow cytometer. c Bars graph (fluorescence
intensity) values ± SD obtained from B (three independent experi-
ments). d After the period of treatment, cells were lysed with RIPA
buffer and 30 lg of protein extract was separated on SDS-PAGE.
Western blot analysis were performed using anti-PARP and anti-
GAPDH (endogenous control). *p B 0.05, **p B 0.01, and
***p B 0.001 (Ctrl vs Amblyomin-X or Amblyomin-X vs inhibitors)
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incubation time. In SK-MEL-28 cells and Mia-PaCa-2, this
phenomenon was observed after 24 h of Amblyomin-X
treatment (Fig. 2c, d). The blocking of Amblyomin-X
cytotoxicity by BAPTA-AM indicates that calcium
released from intracellular storage (ER, mitochondria) to
cytoplasm plays an important role in mode of action of
Amblyomin-X.
In addition, Amblyomin-X treatment promoted mito-
chondrial dysfunction only in tumor cells, indicating the
involvement of the intrinsic pathway of apoptosis. Several
antitumor drugs have been reported to work via activation
of the intrinsic pathway of apoptosis [32]. The results
supported our prediction because cytochrome-c released in
tumor cells were treated with Amblyomin-X, however,
only after 48 h of treatment. This suggests that no adequate
response was achieved to generate drastic changes in
mitochondrial potential in early periods of treatment (4 and
24 h), but that which intensifies over longer periods of
treatment and later become sufficient to release this pro-
apoptotic factor. The cytochrome-c released into cytosol
and forms a complex with APAF-1 and pro-caspase-9,
called the apoptosome, which promotes the cleavage of
pro-caspase-9 and the release of active caspase-9 [44].
Once activated, caspase-9 activates caspase-3, which leads
to apoptosis [45]. The activation of caspases could be
involved in mechanism of action of Amblyomin-X, since
its cytotoxicity was blocked by caspases inhibitors and
Amblyomin-X treatment caused caspase-3/7 activation and
PARP cleavage. However, in SK-MEL-28 cells, cleavage
of PARP was detected prior to the release of cytochrome-c,
suggesting the activation of caspase-3 pathway through
other components, such as ER stress (caspase-4) and death
(caspase-8) [32].
Even with all this evidence, it is not possible to establish a
clear relationship between ER stress, elevations of [Ca2?]i,
mitochondrial dysfunction, and caspase activation induced
by Amblyomin-X. Notwithstanding, there is no way of rul-
ing out the possibility of activation of these pathways sep-
arately by Amblyomin-X, and that their individual cellular
response converge in apoptosis, or proceed until reaching
the point of synergy among the pathways. However, more
investigations are necessary to define the sequence of these
events. In conclusion, these investigations might help in
further understanding of the antitumor properties of
Amblyomin-X, which has potential to become a promising
candidate for the treatment of cancer.
Conclusion
Many investments and efforts are made to improve cancer
therapy; for example, in recent years, dozens of proteasome
inhibitors have been synthesized and studied. Herein, we
have demonstrated that Amblyomin-X, a proteasome
inhibitor disturbs cell homeostasis and overlaps the tumor
resistance mechanisms, culminating in cell death. Although
cells upon Amblyomin-X treatment present differences in
time and intensity of pro-apoptotic effects, the mechanism
of action observed is similar in the tumor cells studied.
Interestingly, all investigations on Amblyomin-X have
shown its toxicity to tumor cells, but not to normal human
fibroblasts cells, reinforcing its selectivity to tumor cells.
Thus, Amblyomin-X could be a promising candidate for
the treatment and study of cancer.
Experimental section
Amblyomin-X production
The homogeneous recombinant protein was prepared as
reported elsewhere [25].
Cell lines and culture conditions
Human’s melanomas (SK-MEL-28 and SK-MEL-5) and
pancreatic adenocarcinomas (MIA-PaCa-2, Panc1, BxPC3,
AsPC1) cells were obtained and cultured according to
instructions of American type culture collection (ATCC,
Manassas, VA). Human normal fibroblasts were isolated
from biopsy dermal tissue of adult subjects. Cells were
maintained in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 15 % fetal bovine serum and
1 % of antibiotic solution (0.1 mg/mL of streptomycin and
100U/mL of penicillin). All cell lines were routinely grown
in a humidified 5 % CO2 incubator at 37 C.
Cell viability assay
Cell viability was measured by MTT tests as described
elsewhere [24]. In order to investigate the caspase inhibi-
tors or chelating intracellular calcium, SK-MEL-28 and
Mia-PaCa-2 cells were seeded in 96-well plates (104 cells/
well) and pre-incubated with specific caspase-3 inhibitor
DEVD-CHO (10 lM), pan caspase inhibitor ZVAD-FMK
(50 lM), or with BAPTA-AM (10 lM) for 30 min.
Finally, cell viability was measured by MTT assay.
Quantitative real-time PCR analysis
Tumor cells (SK-MEL-28 and Mia-PaCa-2) and human
fibroblast were harvested at various time points after
treatment with Amblyomin-X. Subsequently, the total
RNA was extracted from these cells lines using the RNeasy
kit (Qiagen, Netherlands) and DNase treatment was carried
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out. Then, cDNA strands were constructed using a
SuperScript III First-Strand Synthesis kit (InvitrogenTM,
Life Technologies Inc., USA), according to manufacturer’s
instructions. Finally, the samples were applied in a SYBR
green (Applied Biosystems, USA)-based reaction with
specific and validated primers to evaluate mRNA levels of
genes coding for ER stress proteins. The GAPDH (Glyc-
eraldehyde-3-phosphate dehydrogenase) gene expression
level was used as normalize control. The experiments were
conducted by Step One Plus PCR real-time system (Ap-
plied Biosystems, USA) with the following cycle condi-
tions: 10 min at 95 C, followed by 40 cycles of
denaturation of 15 s at 95 C, 30 s at 60 C, and finally
30 s at 72 C. The relative mRNA levels of gene expres-
sion were calculated using the Pfaffl method [46].
Indirect immunofluorescence
ER stress-induced transport ATF-6a was verify according
previous reports [47]. Tumor cells were grown on cover-
slips in 15 9 15 mm 6-well plate and treated with
Amblyomin-X (1 lM) for 4 and 24 h; or MG-132
(2.5 lM) for 24 h, a known proteasome inhibitor; or
thapsigargin (1 lM) for 24 h, a selective inhibitor of
endoplasmic reticulum Ca2?-ATPase, which was reported
to induce ER stress. Cells were washed twice with 1X PBS
and fixed with 4 % paraformaldehyde for 15 min at room
temperature. The washing step was repeated and, then cells
were incubated with a cell permeabilization solution
(0.1 % saponin in PBS 1X) for 15 min at room tempera-
ture. Samples were washed and were incubated with
blocking solution 1 % BSA for 30 min at room tempera-
ture. Following, the primary antibody was incubated
overnight at 4 C in (i) anti- human- ERGIC 53 mouse
(Origen, Netherlands) 1:100; (ii) anti-human ATF-6a rab-
bit (Santa Cruz Biotechnology, Inc., USA) 1:50. A washing
procedure was carried out and samples were incubated with
secondary antibodies Alexa Fluor 555 goat anti-rabbit
(InvitrogenTM Life Technologies Inc., USA), and Alexa
Fluor  488 rabbit anti-mouse (InvitrogenTM Life Tech-
nologies Inc., USA), both at 1:200 dilution for 1 h at room
temperature in the dark. Cells were washed and one drop of
solution anti-fade mounting VECTASHIELD (Vector
Labs, USA) was applied on the slide with cover slip con-
taining cells facing down and, then, sealed. The analysis
was performed in LSMS Zeiss 510 confocal microscope
(Zeiss, Germany).
Western blot analysis
Total cellular proteins were extracted from tumor cells
treated with Amblyomin-X or PBS 1X (Ctrl) using strong
RIPA lysis buffer (150 mM NaCl, 1.0 % IGEPAL CA-
630, 0.5 % sodium deoxycholate, 0.1 % SDS, and 50 mM
Tris, pH 8.0.) and were quantified by BCA (bicinchoninic
acid assay) using the Pierce Microplate BCA Protein
Assay kit (Thermo Scientific, USA). Then, protein samples
(30 lg) were subjected to standard SDS-PAGE and were
transferred onto a polyvinylidene difluoride membrane (GE
Healthcare, USA). For detection of protein of interest,
primary polyclonal antibodies were applied on membrane.
Primary antibodies used were anti-GRP78 (Santa Cruz
Biotechnology, Inc., CA, USA), anti-GADD153 (Santa
Cruz Biotechnology, Inc., USA), anti-PARP (Cell Signal-
ing, MA, USA), and anti-GAPDH (Sigma-Aldrich, MO,
USA). Bound antibodies were detected by chemolumines-
cence method using a homemade solution (1.5 M Tris pH
8.9; 20 mM p-coumaric acid, 125 mM luminol, and 30 %
peroxide hydrogen). The images were acquired at each 10 s
exposure in the LAS 4000 equipment (GE Healthcare,
USA), employing the ImageQuant software.
Preparation of protein extract for cytochrome-c
measurement
SK-MEL-28 and Mia-PaCa-2 cells were treated with
Amblyomin-X. Cells were harvested and were washed
twice in PBS. For cytoplasmic cytochrome-c measurement,
a modified extraction procedure was used compared to the
one we employed for the analysis of GRP78, GADD153,
and PARP. Briefly, to obtain a cytoplasmic proteins frac-
tion, cells were re-suspended in relatively weak lysis buffer
(HEPES–KOH 10 mM; pH 7.4, EDTA 0.1 mM; bis-
etilenoglicol (b-aminoethyl ether); EGTA 1 mM; sucrose
250 mM; orthovanadate (Na3VO4) 1 mM, PMSF 1.0 mM,
and dithiothreitol (DTT) 10 mM) and were incubated on
ice for 15 min. Samples were then centrifuged at 10,000 g
for 15 min at 4 C to sediment unbroken cells, nuclei, and
the heavy membrane fractions containing mitochondria or
other cellular compartments. Supernatants containing
mostly cytoplasmic proteins were collected and were sub-
jected to immunoblot analysis using anti-cytochrome-c
(Santa Cruz Biotechnology, Inc., USA).
Measurements of changes in free intracellular
calcium concentration ([Ca21]i) by microfluorimetry
Changes in cytosolic calcium concentration ([Ca2?]i) were
monitored by microfluorimetry, described elsewhere [48].
For this purpose, SK-MEL-28 and human fibroblast cells
were transferred into 96 black-well plates (Costar, UK) at a
density of 5 9 104 cells per well in serum-free medium.
Cells were then kept with FlexStation Calcium Kit con-
taining 2.5 mM probenecid for 60 min at 37 C. Before
and after addition of Amblyomin-X or TAPS, fluorescence
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of samples was excited at 485 nm, and fluorescence
emission was measured at 525 nm.
Measurement of intracellular Ca21 levels by flow
cytometry
Tumor cells (SK-MEL-28 and Mia-PaCa-2) were grown
with 0.5 lM Amblyomin-X or PBS for 4 and 24 h. Cells
were washed with PBS, and incubated with 10 lM of
calcium green-1-AM (Molecular Probes, OR). Calcium
green-1-AM is labeled with calcium indicator molecule
that changes fluorescence upon binding Ca2? in the pres-
ence of 0.2 % of non-ionic surfactant pluronic acid F-127
(Sigma-Aldrich, MO, USA). Stained cells were examined
on flow cytometer FACSCalibur (Becton, Dickinson and
Company, CA, USA). For data analyses, FlowJo (FlowJo,
LLC, OR, USA) software was employed.
Mitochondrial potential measured
The rhodamine 123 (123Rh) is a lipophilic cationic fluo-
rochrome that is readily incorporated into mitochondria in
manner-dependent mitochondrial membrane potential [49,
50]. It is a cationic fluorochrome, which is attracted by a
high negative electrical potential present in the mitochon-
drial membrane. Changes in mitochondrial membrane
integrity cause diffusion of 123Rh from mitochondria to
cytosol and it can be detected by a decrease in fluorescence
[49, 50]. Briefly, after 4 or 24 h of Amblyomin-X treatment
(0.5 lM), the tumor cells (SK-MEL-28 and Mia-PaCa-2)
and human fibroblast cells (105 cells/plate) were suspended
in 300 lL FACs buffer and incubated with 123Rh probe
(200 ng/mL) in a humidified 5 % CO2 incubator for
30 min at 37 C. Finally, cells were washed in cold PBS,
and mitochondrial potential was measured using a flow
cytometer FACSCalibur (Becton e Dickson, CA, USA).
For data analyses, FlowJo (FlowJo, LLC, OR, USA) soft-
ware was employed.
Caspase activation
To verify caspase activity, CellEventTM Caspase-3/7 Green
Detection Reagent (Molecular Probes Inc. USA) was used
according to manufacturer’s instructions. Briefly, tumor
cells were treated with Amblyomin-X (1 lM) for 4 and
24 h; or with MG-132 (2.5 lM) for 24 h; or with TAPS
(1 lM) for 24 h. Then, tumor cells were stained with
CellEventTM Caspase-3/7 Green Detection Reagent for
30 min at 37 C. The fluorogenic response resulting from
DEVD peptide cleavage was measured by flow cytometer
FACSCalibur (Becton e Dickson, CA, USA). For data
analyses, FlowJo (FlowJo, LLC, OR, USA) software was
employed.
Statistical analysis
Comparisons were carried out using Two-way ANOVA
analysis followed by Tukey’s Post Hoc test or t-Test,
employing the GraphPad Prism 5.0 software (GraphPad
Software Inc., San Diego, CA). The criteria for statistical
significance were set up as *p B 0.05, **p B 0.01, and
***p B 0.001.
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